Lupin Reports 6.7% Net Profit Growth in Q2 FY24-25, Strengthens Financial Position

Lupin, a prominent player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation adjustment that reflects its evolving market position and financial metrics. The company has showcased a consistent trajectory of performance, highlighted by a net profit growth of 6.7% in the second quarter of FY24-25, marking its eighth consecutive quarter of positive results.
Key financial indicators reveal a strong operational foundation, with a Debt to EBITDA ratio of 0.70 times, suggesting a solid capacity to manage debt obligations. The operating cash flow has reached Rs 3,648.36 crore, while the return on capital employed (ROCE) is reported at 18.68%. Furthermore, the operating profit to interest ratio stands at 18.91 times, underscoring the company's robust financial health.

Lupin's return on equity (ROE) is noted at 16.8, accompanied by a price-to-book value of 6.1, which positions the stock as an appealing option for investors. Over the past year, the stock has delivered a notable return of 49.17%, significantly outpacing the BSE 500 index. The high institutional holdings at 46.79% reflect a strong confidence in the company's fundamentals, contributing to its competitive performance in both the long and near term.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.